Pantoprazole Sodium Raw Materials Powder 138786-67-1

CAS:138786-67-1

MF: C16H14F2N3NaO4S

MW:405.35

EINECS:604-093-4

Specification: 99% min Pantoprazole Sodium Powder

Sample: Pantoprazole Sodium Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Pantoprazole Sodium Powder Usage and Synthesis.

Pantoprazole sodium refers to 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole sodium salt, which is a kind of H+,K+-ATPase inhibitor, and it can inhibit the gastric acid secretion produced by the stimulation of various factors, such as histamine, gastrin and acetylcholine, and it is used for the treatment of the diseases related to the disorders of gastric acid secretion, and it has the advantages of high curative rate, rapid onset of action, and small adverse reactions.

Uses and functions of Pantoprazole Sodium.

Antacids and anti-ulcer drugs for gastric and duodenal ulcers.

Pharmacological Effects of Pantoprazole Sodium Raw.

It inhibits gastric acid secretion by specifically acting on the mural cells of the gastric mucosa and reducing the activity of H+-K+-ATPase in the mural cells. Compared with omeprazole, pantoprazole sodium has a weaker inhibitory effect on cytochrome P450 enzymes. Pantoprazole sodium, together with omeprazole and lansoprazole, is a gastric mural cell proton pump inhibitor that is relatively stable under neutral and weakly acidic conditions, and rapidly activated under strongly acidic conditions, and its pH-dependent activation properties allow for a better selectivity of its action on H+, K+-ATPase

1, when this product and bioavailability depends on the PH value of the drug (such as ketoconazole) at the same time, should take into account the effect of this product on its absorption.

Pantoprazole is metabolised in the liver by the cytochrome P450 enzyme system, therefore any other drug metabolised by this enzyme system cannot be excluded from the possibility of interaction with this product. Such drugs, such as carbamazepine, caffeine, Valium, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, nifedipine, phenylpropylcoumarin, phenytoin, theophylline, warfarin, and oral contraceptives have been tested in clinical practice, but no clinically significant interactions between pantoprazole and them were observed.

3, Pantoprazole did not interact with concomitantly used antacids.

Production method of Bulk Pantoprazole Sodium Powder.

Take about 0.2g of the product, weighed accurately, placed in a 20ml headspace injection bottle, add 2ml of internal standard solution to dissolve, sealed, as a test solution. Separately weighing ether, acetone, dichloromethane, trichloromethane, toluene (toluene is insoluble in water. Can be dissolved with the appropriate amount of dimethylformamide and then dispersed in the solution) appropriate amount of each, with the internal standard solution made of each 1ml, respectively, ether 500µ g, acetone 500µ g, dichloromethane 60µ g, trichloromethane 6µ g, toluene 90µ g of the control product mixed solution, a precise measure of 2 ml, and place 20ml headspace injection bottle, sealed, as the control solution. Take the control solution and test solution headspace injection, record the chromatogram, according to the internal standard method to calculate the peak area of the test in acetone, ether, dichloromethane, chloromethane, toluene content, containing dichloromethane shall not be more than 0.06%, chloromethane shall not be more than 0.006%, toluene shall not be more than 0.089%, ether, acetone shall not be more than 0.5%.